Latest stories on MESO
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain | MESO Stock News
StockTitan63 · neutralproduct/pr
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
Seeking Alpha67 · bullishproduct/pr
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Business Insider55 · neutralgeneral
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 | MESO Stock News
StockTitan59 · neutralearnings
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility | MESO Stock News
StockTitan59 · neutralgeneral
Mesoblast Showcases Profitable Ryoncil Launch and Expanding Cell Therapy Pipeline in June 2026 CEO Presentation
TipRanks67 · bullishproduct/pr
Mesoblast Limited (MESO) Presents at ASX CEO Connect June 2026 - Slideshow
Seeking Alpha50 · neutralgeneral